tbuckley/cabot-search huggingface dataset:
Abstract 14: Nucleolin phosphorylation by CK2 is important for its role in regulating apoptosis
Authors: Esther Akinwunmi, Shu Xiao, Yuqi Guo, Xin Li, Anjana D. Saxena
Journal: Cancer Research (2015)

Abstract Nucleolar phosphoprotein nucleolin integrates critical cellular processes including gene expression, ribosome biogenesis, proliferation and the cellular response to stress. Elevated levels of nucleolin are found in a variety of tumors. Nucleolin has distinct mechanisms in p53 regulation to influence cell survival: In “normal unstressed” cells (with hyper-proliferative signals but no obvious DNA damage), nucleolin stabilizes p53 and induces apoptosis. Under DNA-damage however, nucleolin can cause translational repression. The translational repression is overcome upon DNA damage in part, possibly due to nucleolin translocation to the nucleoplasm, altered interactions with ribosomal protein, RPL26 and/or p53-antagonist, HDM2. In contrast, nucleolin binding to AU rich elements (AREs) of anti-apoptotic BCL2-mRNA stabilizes BCL2, leading to cell survival. Importantly, increased nucleolin phosphorylation by the interphase kinase CK2 is finely regulated in exponentially dividing cells; however, role of nucleolin phosphorylation remains largely unexplored in cell survival. We recently demonstrated that phosphorylation deficient nucleolin mutant confers dominant negative effect on cell proliferation. In this study, we dissect the role of nucleolin phosphorylation in regulating p53-signaling pathway. Our pathway specific qRT-PCR-array analyses indicate that expression of phosphorylation-deficient nucleolin mutant resulted in an increased gene expression in the apoptosis, DNA damage and repair pathways that are downstream to p53 activation. We further elucidate that targeting nucleolin phosphorylation by CK2 initiates an increased expression of BH3-only proteins: p53-transcriptional targets e.g. BID and PUMA. Interestingly, an increased expression of BIM, a p53-independent target that is required during DNA damage induced cell death is evident with NCL expression regardless of its phosphorylation status. This is the first step in understanding nucleolin-phosphorylation mediated regulation of gene expression in the p53-pathway to control cell proliferation. This information will be useful in identifying new targets that can be either directly (via RNA binding) or indirectly (through other proteins or gene expression) regulated by nucleolin phosphorylation. Citation Format: Esther Akinwunmi, Shu Xiao, Yuqi Guo, Xin Li, Anjana D. Saxena. Nucleolin phosphorylation by CK2 is important for its role in regulating apoptosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 14. doi:10.1158/1538-7445.AM2015-14
Primary Treatment of Nasolacrimal Duct Obstruction with Probing in Children Younger than 4 Years
Authors: Repka Mx, Chandler Dl, Beck Rw, Crouch Er rd, Donahue S, Holmes Jm, Lee K, Melia M, Quinn Ge, Sala Na, Schloff S, Silbert Di, Wallace Dk
Journal: Ophthalmology (2007)
Abstract B38: Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition
Authors: Milos Dokmanovic, Yun Wu, Yi Shen, Jieqing Chen, Dianne S. Hirsch, Wen Jin Wu
Journal: Clinical Cancer Research (2015)

Abstract Trastuzumab is a humanized recombinant monoclonal antibody directed against extracellular region of ErbB2 and used for the treatment of different ErbB2-positive cancers. Based on literature reports and our clinical data from trastuzumab neoadjuvant studies, increased ErbB2-Y1248 phosphorylation is associated with a better response to trastuzumab in patient samples. Also, in trastuzumab-sensitive cell lines (SKBR3 and BT474), increased basal level and trastuzumab-mediated increase in ErbB2-Y1248 phosphorylation was readily detectable compared to trastuzumab-resistant cell line model (JIMT1). The mechanisms of trastuzumab-induced ErbB2-Y1248 phosphorylation and the role of ErbB2-Y1248 phosphorylation in trastuzumab sensitivity/resistance are still incompletely understood. We demonstrate that trastuzumab activates ErbB2 kinase activity in trastuzumab-sensitive cells, which may further contribute to trastuzumab-mediated ErbB2-Y1248 phosphorylation. However, blocking ErbB1/ErbB2 kinase activity with Lapatinib, a small molecule tyrosine kinase inhibitor only partially reduced trastuzumab-mediated ErbB2-Y1248 phosphorylation. This led to the discovery of a previously unappreciated relationship between trastuzumab and Csk-homologous kinase (CHK), a non-receptor tyrosine kinase also known as MATK. We establish that trastuzumab treatment promotes interaction between ErbB2 and CHK in trastuzumab-sensitive but not in trastuzumab-resistant cells despite similar CHK expression levels in both types of cells. Mimicking trastuzumab, CHK overexpression also induces ErbB2-Y1248 phosphorylation, Akt downregulation and cell growth inhibition and further stimulated trastuzumab-mediated reduction in total ErbB2 levels in trastuzumab sensitive cells. Also, CHK overexpression combined with trastuzumab exerts an additive effect on cell growth inhibition in trastuzumab-sensitive but not in trastuzumab-resistant cells. Understanding of the molecular mechanisms of trastuzumab mediated ErbB2 phosphorylation changes may suggest novel therapeutic approaches in the treatment of trastuzumab resistant cancers. Disclaimer: The information presented in this article reflects the views of the authors and does not represent the policy of the U.S. Food and Drug Administration. Citation Format: Milos Dokmanovic, Yun Wu, Yi Shen, Jieqing Chen, Dianne S. Hirsch, Wen Jin Wu. Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; Jun 18-21, 2014; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(4 Suppl): Abstract nr B38.
Abstract 16129: Feasibility and Safety of Treatment With an Intracoronary Infusion of Adipose Derived Regenerative Cells (ADRC) in Patients With an Acute ST-Elevation Myocardial Infarction (ADVANCE study)
Authors: Henricus J Duckers, Piotr Musialiek, Daiusz Dudek, Janusz Kochman, Steven Kesten, Giuilo Pompilio
Journal: Circulation (2014)

Objectives: The ADVANCE clinical trial sought to define the safety, feasibility and efficacy of an intracoronary infusion of adipose derived regenerative cells in patients admitted with an acute ST-elevation myocardial infarction (STEMI) within 24 hours of successful primary PCI. Methods: In this randomized, double-blind, placebo-controlled trial (n=23, 2:1 randomization), within 24 hours of successful primary PCI following STEMI, a small volume liposuction was performed for fat harvest and ADRC isolation by an automated Celution® System, and intracoronary infusion within 12 hours of the liposuction. Results: 23 patients were enrolled to date (all male, age 58 years, BMI 28 kg/m 2 ). The liposuction procedure data are shown in the table TEMI patients were routinely treated with dual anti platelets and heparin. The decline in hemoglobin following the liposuction procedure from baseline over the 10 hours following the procedure was 10.2% ±7.6 (mean ± SD) Although two patients had &gt;20% of Hb decline at anytime (maximum 20.8%), one of these patients returned to within 10% of baseline by 10 hours without transfusion. The liposuction procedure was completed in all but one patient (terminated early due to hypotension - resolved with termination of procedure). IC infusion of the ADRC suspension was performed successfully in all patients. No impediment of coronary TIMI flow was observed during or following cell infusion of these mesenchymal-like cells. No ventricular arrhythmias were observed during cell infusion. No major adverse cardiac or cerebral events (MACCE) occurred within 30 days of the procedures. Conclusion: Limited liposuction to harvest fat for ADRC stem cell isolation and subsequent intracoronary infusion of these autologous ADRCs can be performed safely in patients with acute STEMI under dual antiplatelets therapy, demonstrating feasibility of the therapeutic application of point-of-care cell therapy using ADRCs.
Abstract 1136: Relationship between the Spectral Characteristics of Atrial Fibrillation and Atrial Tachycardias That Occur after Catheter Ablation of Atrial Fibrillation
Authors: Kentaro Yoshida, Aman Chugh, Magnus Ulfarsson, Eric Good, Krit Jongnarangsin, Frank Pelosi, Frank Bogun, Fred Morady, Hakan Oral
Journal: Circulation (2008)
Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy Commentary: Promising results but wider recruitment needed
Authors: P. Lahteenmaki, M. Haukkamaa, J. Puolakka, U. Riikonen, S. Sainio, J. Suvisaari, C. G. Nilsson, A. Prentice
Journal: BMJ (1998)

# Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy {#article-title-2} Objectives: To assess whether the levonorgestrel intrauterine system could provide a conservative alternative to hysterectomy in the treatment of excessive uterine bleeding. Design: Open randomised multicentre study with two parallel groups: a levonorgestrel intrauterine system group and a control group. Setting: Gynaecology departments of three hospitals in Finland. Subjects: Fifty six women aged 33-49 years scheduled to undergo hysterectomy for treatment of excessive uterine bleeding. Interventions: Women were randomised either to continue with their current medical treatment or to have a levonorgestrel intrauterine system inserted. Main outcome measure: Proportion of women cancelling their decision to undergo hysterectomy. Results : At 6 months, 64.3% (95% confidence interval 44.1 to 81.4%) of the women in the levonorgestrel intrauterine system group and 14.3% (4.0 to 32.7%) in the control group had cancelled their decision to undergo hysterectomy (P<0.001). Conclusions : The use of the levonorgestrel intrauterine system is a good conservative alternative to hysterectomy in the treatment of menorrhagia and should be considered before hysterectomy or other invasive treatments. # Commentary: Promising results but wider recruitment needed {#article-title-10}
Abstract 3589: Adipose stem cell-derived interferon gamma alters breast epithelial stem cell hierarchy
Authors: Manjushree Anjanappa, Riesa M. Burnett, Stephanie Merfeld-Clauss, William A. Wooden, Keith L. March, Sunil Tholpady, Harikrishna Nakshatri
Journal: Cancer Research (2014)

Abstract Autologous adipose stem cell transplantation is increasingly being used for soft tissue reconstruction, particularly after mastectomy. However, a recent study demonstrated recurrence of invasive ductal carcinoma in the breast within four months of autologous fat grafting. Previous studies have documented how cancer cells commandeer adipose stem cells (ASC) to support their survival by altering extracellular matrix composition and stiffness. This study focused on delineating the effects of ASCs on the self-renewal capacity of breast epithelial cells. The immortalized breast epithelial cell line MCF-10A, MCF-10A overexpressing Slug, and MCF-10A overexpressing SRC were examined using a mammosphere assay and flow cytometry for the effects of ASCs on their self-renewal and stem-luminal progenitor-differentiated cell surface marker profile. MCF-10A-Slug cells provided a unique model system to study breast epithelial cell dedifferentiation as Slug functions downstream of the breast cancer susceptibility gene BRCA1 and is a major suppressor of progenitor cell lineage commitment and differentiation. Interestingly, results with these established cell lines were reproduced in primary breast epithelial cells isolated from a high-risk patient. We show that secreted factors from ASCs promote self-renewal of all cell types examined. ASC co-culture or treatment with ASC conditioned media (CM) altered the number of CD49fhigh/EpCAMlow stem-like and CD49fmedium/EpCAMmedium luminal progenitor cells in 2D culture and mammosphere assays. ASCs secrete Interferon gamma (IFNγ), CD40 ligand, IL-23 and SERPINE1. Among these factors, only IFNγ treatment altered stem cell hierarchy; while MCF-10A-Slug cells displayed only luminal progenitor phenotype, cells treated with IFNγ contained a distinct stem-like cell population. These results suggest that paracrine activity of adipose stem cell-derived factors can either enhance dedifferentiation and promote proliferation of dormant tumor cells or predispose normal cells to transformation by blocking differentiation. Financial support: Susan G. Komen For the Cure SAC110025 and Zeta Tau Sorority (HN) Citation Format: Manjushree Anjanappa, Riesa M. Burnett, Stephanie Merfeld-Clauss, William A. Wooden, Keith L. March, Sunil Tholpady, Harikrishna Nakshatri. Adipose stem cell-derived interferon gamma alters breast epithelial stem cell hierarchy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3589. doi:10.1158/1538-7445.AM2014-3589
Constructive Conscious Control of the Individual.
Authors: F. Matthias Alexander
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An intermediate methylation signature is associated with improved patient survival and a distinct global mRNA expression profile in glioblastoma: An interim analysis of The Cancer Genome Atlas data
Authors: Christopher Pelloski, Andreana Rivera, Krishna Bhat, Erik Sulman, WK Alfred Yung, Jonas Almeida, Pablo Fiere, Mark Gilbert, Steven Baylin, Peter Laird, Kenneth Aldape
Journal: Clinical Cancer Research (2008)

PL04   The Cancer Genome Atlas (TCGA) project is an ongoing study with a goal of describing the variety of molecular aberrations that occur in glioblastoma (GBM) by the use of high-throughput molecular platforms on clinically annotated tumor specimens. One such platform includes methylation of approximately 3,000 CpG islands using the Illumina Golden Gate array. Data were available for 183 GBM patients for an interim analysis. Data were filtered to include the CpG islands that showed high variation among the samples, resulting in 143 CpG islands, which were subject to unsupervised hierarchical clustering. This cluster analysis revealed 3 groups of tumors differing according to the degree of overall methylation. One group exhibited extensive methylation, a second showed very low levels of methylation and a third was defined by hyper-/hypomethylation of specific CpG islands (the intermediate group). The intermediate group was further characterized by methylation of a specific set of genes that were unmethylated in the other groups, and included  HRB2 ,  NETO2 ,  WNT10B ,  LAYN  and  PCDHB2 .  A survival analysis showed that the intermediate group had a significantly improved overall survival (p FABP5 ,  RBP1 ,  FAS ,  THBS1  and  ICA1 . Among the 13 genes specifically methylated in the other 2 groups, 3 genes (23%) showed a concordant decrease in expression ( NPY ,  NEFL  and  TUSC3 ). Interestingly, the global gene expression profile of the intermediate methylation subgroup greatly differed from the other 2 subgroups. In particular, this group showed increased expression of genes whose over-expression we have previously found to be correlated with improved outcome, including  SNAP91 ,  DCX ,  RP11-35N6.1 ,  TUSC3 , and  RTN1 , genes associated with neural development. Genes previously associated with poor outcome, including  CHI3L1  (YKL-40),  PDPN ,  NNMT , and  TIMP1  as well as additional extracellular matrix/mesenchymal genes were under-expressed in this group. In all, there were over 200 genes with a ≥2.5-fold difference in mRNA expression between the intermediate subgroup versus the other 2 groups, but minimal gene expression variability between the high and low methylation groups, respectively.  Taken together, these data suggest that CpG methylation profiles represent a source of robust biomarkers in GBM, are extensively intertwined with the global gene expression profile, and corroborate our previously described concept of a prognostically unfavorable, mesenchymal subgroup and favorable, proneural subgroup. Importantly, it also provides proof-of-concept that the cross-platform analyses made possible by TCGA will lead to new insights regarding the molecular complexity of GBM.
Introduction to periodontal epidemiology
Authors: Raul Garcia, Thomas Dietrich
Journal: Periodontology 2000 (2011)

Abstract There is growing interest in, and appreciation of, the importance of epidemiological science in furthering our understanding of periodontal diseases. There is also interest in applying modern epidemiological methods to identify periodontal disease risk factors, prognostic factors and the long‐term outcomes of care, as well as periodontal–systemic associations. This volume combines critical reviews of selected areas of contemporary interest with targeted methodologically focused articles, in order to provide a valuable reference text to guide readers in their own critical assessment of new scientific findings, as well as to assist investigators in the design and analysis of their own original research in periodontal epidemiology. The 11 review articles that comprise this volume were selected with this goal in mind. They aim to inform readers on the methodological rigor that needs to be applied, both in the design of epidemiological studies and interpretation of their results, and the limitations to the inferences that may be drawn from epidemiological studies. Despite its various limitations, the field of periodontal epidemiology is expected to continue to grow in importance and relevance. There remains a need for well‐designed, carefully analyzed and correctly interpreted observational studies, including longitudinal cohort studies and case–control studies, in order to adequately understand both the causes of periodontal disease and the associations between periodontal disease and systemic disease in populations.
Abstract P107: Automated Detection of the Culprit Artery Associated With ST Elevation Myocardial Infarct Using a New Electrocardiogram Diagnostic Algorithm
Authors: Mohamud R Daya, Ronald H Startt, Selvester, Richard E Gregg, Sophia H Zhou
Journal: Circulation (2009)

Introduction: The ultimate goal of ST elevation myocardial infarction (STEMI) management is to open the occluded artery and restore blood flow. Recent AHA recommendations suggest that automated dia...
First new screening recommendations from the third US Preventive Services Task Force
Authors: David Atkins
Journal: BMJ (2003)

This article originally appeared in BMJ USA 

The US Preventive Services Task Force (USPSTF) is an independent panel first convened in 1984 by the US Department of Health and Human Services to develop evidence-based recommendations for clinicians about preventive health care. The Guide to Clinical Preventive Services, released in 19891 and completely revised in 1996,2 assessed more than 200 common screening tests, counseling interventions, immunization strategies, and medications for prevention of disease. The primary audience for USPSTF recommendations continues to be clinicians in primary care settings, but many professional societies, health plans and insurers, quality organizations, and policy makers have come to rely on the USPSTF for rigorous and objective guidance about which preventive services should be routinely incorporated into clinical practice.3

The third USPSTF was convened in late 1998 by the Agency for Healthcare Research and Quality (AHRQ). A priority-setting process, which included review by staff and input from outside experts and organizations, found that more than 50 of the 70 chapters in the 1996 Guide were in need of substantial updating; it also identified a number of high-priority new topics. The first new and revised recommendations from the USPSTF resulting from this work, along with summaries of the supporting evidence, have just been released in a special supplement to the American Journal of Preventive Medicine4 and on AHRQ's web site (www.ahrq.gov/clinic/uspstfix.htm). 

Detailed descriptions of the methods by which the USPSTF develops its recommendations are available on the USPSTF web site and in the recent supplement.5 A number of specific features distinguish the USPSTF recommendations from those of many other organizations. The USPSTF uses an explicit process to define key questions and specify the necessary evidence to establish that a given service is effective. Research teams at two evidence-based practice centers supported by …
A Public Health Perspective on a National Precision Medicine Cohort
Authors: Muin J. Khoury, James P. Evans
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal